Related Experiment Video

Updated: May 23, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K

STAT3 Sustains Tumorigenicity Following Mutant KRAS Ablation

Stephen D'Amico, Varvara Kirillov, Jingxuan Liu

    Biorxiv : the Preprint Server for Biology
    |March 10, 2025
    PubMed

    Insights

    Targeting KRAS mutations in cancer requires combined inactivation of STAT3 to eliminate malignant identity and promote tumor clearance. This approach enhances immune rejection for effective cancer therapy.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Immunology

    Background:

    • Oncogenic KRAS mutations are drivers of aggressive cancers, but their inactivation alone is insufficient for tumor control.
    • Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge due to tumor persistence after KRAS inhibition.
    • STAT3 has been implicated in maintaining cancer stemness and immune evasion, crucial for tumor survival.

    Purpose of the Study:

    • To investigate the role of STAT3 in maintaining malignant identity in KRAS-mutated cancers.
    • To determine if combined inactivation of KRAS and STAT3 can lead to tumor regression.
    • To elucidate the mechanisms by which STAT3 contributes to cancer persistence after KRAS inactivation.

    Main Methods:

    • CRISPR-mediated gene editing to ablate mutant KRAS and STAT3 in a PDAC model.
    • Assessment of tumor progression, malignant identity, and immune rejection in vivo.
    • Analysis of core transcriptional programs affected by combined KRAS and STAT3 loss.

    Main Results:

    • CRISPR-mediated ablation of mutant KRAS terminated tumor progression only when STAT3 was concomitantly inactivated.
    • Combined KRAS and STAT3 loss disrupted a critical cancer cell transcriptional program, impairing tumor growth in mice.
    • Tumor cells lacking both KRAS and STAT3 exhibited enhanced immune rejection, leading to tumor clearance.

    Conclusions:

    • STAT3 acts as a critical enforcer of oncogenic identity in KRAS-ablated tumors, rather than solely providing transformation features.
    • The combined inactivation of KRAS and STAT3 disrupts essential cancer cell programs, leading to loss of malignant identity.
    • This study reveals a vulnerability in KRAS-driven cancers, suggesting STAT3 as a target for combination therapies to achieve durable tumor control.

    More Related Videos

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

    Published on: March 26, 2014

    23.2K
    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    13.6K

    Related Concept Videos

    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    6.1K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    4.4K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.7K
    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    7.3K
    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
    4.7K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    3.4K